All News

Patients with malignant pleural mesothelioma tended to have prolonged benefit when treated with Keytruda plus Lenvima in the PEMMELA clinical trial.

The Food and Drug Administration put a full clinical hold on a study of the novel drug FHD-286 in patients with acute myelogenous leukemia and myelodysplastic syndrome after study data showed an increase in a potentially fatal side effect.

When doctors told me that there was no more they could do for my stage 4 lung cancer, I refused to believe them, and wish other patients did the same.

From bald heads paired with lush eyebrows to the typical emaciated patient, there are certain tropes of how cancer is portrayed on TV that bother me, as they do not represent the experiences of everyone with the disease.

CURE® surveyed its audience to see how they cope with fear of cancer recurrence. Here’s what they had to say.

Treatment with Ayvakit was associated with promising outcomes in patients with mastocytosis, according to findings from the PIONEER trial.

My doctor once told me that if you're old enough to fight for your country, then you're old enough to get breast cancer.

Adding the investigational cancer drug lanraplenib to Xospata, if found to be effective, may broaden treatment options for patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.

As I reflect on four years of “warriorhood” since being diagnosed with cancer, I wrote a letter to my younger self and others who are just receiving diagnosis.

The death of “Grease” star Olivia Newton-John from metastatic breast cancer has triggered discussions about the specifics of the disease. Here, CURE® details what metastatic breast cancer is.

The combination treatment demonstrated survival and safety results similar to those of chemotherapy for patients with advanced, untreated follicular lymphoma.

Janet M. McFadden, RN-BC, B.S., MT(ASCP) understands the medical issues her patients are facing. She is calm and compassionate with her patients.

Often patients read online profiles of medical providers to decide where to receive care. In reality, having a nurse like Christine is so much more important.

The FDA has allowed the manufacturer of emavusertib to continue a phase 1/2 study investigating effects of the treatment in patients with lymphoma.

I am still here fighting, fighting hard and I will continue to do so to make sure I have more graduations, more weddings, and more everything that I can squeeze into my precious time left here on earth.

From ESPN analyst Dick Vitale announcing he is cancer-free months following a lymphoma diagnosis to a Speedo-clad race in South Africa to raise awareness for cancer, here’s what’s happening in the oncology space this week.

Not only does she have incredible clinical intuition and ability, but she has a deep compassion and commitment to her patients that is truly unparalleled.

A representative of the company developing the investigational CAR-T cell therapy noted that they hypothesize that the combination “has the potential to further enhance efficacy and provide patients with a chemotherapy-sparing, second-line treatment option.”

Investigators plan to analyze if treatment with an experimental, CAR-T cell therapy is safe and effective in a small group of patients with relapsed or refractory metastatic colorectal cancer.

My choice to not undergo chemotherapy for breast cancer was not an easy one, but looking back, I don’t regret it.

The FDA has set a date to decide whether or not to approve momelotinib for myelofibrosis, a rare type of blood cancer.

Like all good oncology nurse practitioners, she has a deep knowledge of cancer medicine, and I would trust her to care for anyone in my family.

If approved, the Lynparza-based regimen would become the first combination of a PARP inhibitor and a hormonal agent for metastatic castration-resistant prostate cancer.

A patient with metastatic breast cancer recalls the emotional experience of being among the thousands of attendees who gave a standing ovation in an auditorium in Chicago when the results of the phase 3 DESTINY-Breast04 trial — which recently led to the FDA approval of Enhertu in HER2-low disease — were presented at the 2022 ASCO Annual Meeting.

Cancer and COVID-19 took away my yearly “benchmarks” of time, when I fly out to see friends and family.

Prior to my breast cancer diagnosis, my only goal in life was for my son to turn 16 so he could drive me to and from the local bars. Now I can’t help but think that my cancer was meant for me to change my life.

Janet brings our values at Fox Chase Cancer Center to life.

As I recover from the traumatic effects of cancer, I’m realizing that success has much to do with mindset and optimism.

The use of Trodelvy was associated with a significant improvement in survival when compared with physician’s choice of chemotherapy in patients with HR-positive, HER2-negative metastatic breast cancer, according to recently announced study findings.

I was shocked at a recent doctor appointment when practically nobody in the office was wearing a mask.